Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at “Make Whole” Prices

Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at “Make Whole” Prices

AbbVie

Kroger

Merck

GuruFocus is proud to announce that there were three winners of the fourth-quarter Warren Buffett (Trades, Portfolio) contest: Richday101, Chihin and Nicola Guida. Richday101 and Chihin guessed correctly that Buffett (or Ted Weschler, or Todd Combs) purchased AbbVie Inc. (NYSE:ABBV), Merck & Co. Inc. (NYSE:MRK) and Bristol-Myers Squibb Co. (NYSE:BMY).

GuruFocus Announces 3 Winners of 4th-Quarter Warren Buffett Contest

NEW YORK--(BUSINESS WIRE)---- $BMY--BMS Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion

Becton, Dickinson and Co.

Medtronic

Health care companies may not be at the front of mind when thinking of stocks with dividends, but these three are winners. The post 3 High-Quality Health Care Companies With Recession-Proof Dividends appeared first on InvestorPlace.

3 High-Quality Health Care Companies With Recession-Proof Dividends

Apple

Chevron

Verizon

If you own winning stocks, Berkshire Hathaway's legendary investor has a valuable lesson for you.

Own Big Stock Winners? Handle Them the Warren Buffett Way

NEW YORK--(BUSINESS WIRE)---- $BMY--BMS Announces Early Participation Results and Early Settlement of Tender Offers for up to an Aggregate Purchase Price of Up to $4.0 Billion

Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion

Bristol Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.

Bristol Myers (BMY) is an Incredible Growth Stock: 3 Reasons Why

Barrick Gold

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Berkshire Hathaway's (NYSE:BRK.A) (NYSE:BRK.B) latest 13F report was filed last night. The report detailed the conglomerate's equity positions at the end of December 2020.

Buffett's Berkshire Buys Oil, Heathcare and Telecoms in 4th Quarter

Berkshire Hathaway disclosed fourth-quarter buys of Merck, Bristol-Myers, and AbbVie, while exiting Pfizer.

Warren Buffett's Berkshire Hathaway Traded Stock in Pharma, Banks

Bristol Myers Squibb has an impressive portfolio of assets and strong financials. The company has recently wrapped up large acquisitions. The company is focused on redeveloping its portfolio and expects a massive increase in revenue from new businesses.

Bristol Myers Squibb Has Unique Cash Flow Strength

Suncor Energy

T-Mobile US

Wells Fargo

Warren Buffett's Berkshire Hathaway Inc. BRK.ABRK.B loaded up on drug, telecom and oil stocks while trimming its position in Apple Inc. AAPL over the past quarter, according to a Securities and Exchange Commission filing late Tuesday. Berkshire increased its stake in Abbvie Inc. ABBV by 20%, Bristol-Myers Squibb Co. BMY by 11%, and Merck & Co. MRK by 28%.

Berkshire Hathaway ups drug-stock stakes while trimming Apple

Sanofi

Bristol-Myers Squibb Co (NYSE: BMY) and Sanofi SA (NASDAQ: SNY) were ordered to pay the state of Hawaii more than $834 million for illegally marketing their blood-thinning drug Plavix, Bloomberg reports. Hawaii Attorney General Clare Connors' lawyers showed the companies didn't adequately disclose the blood thinner was ineffective for as many as 30% of users in the state, the judge said.

Bristol-Myers, Sanofi Fined $834M In Hawaii Over Plavix: Bloomberg

Baxter

Cigna

Cisco Systems

Home Depot

Johnson & Johnson

McDonald's

Mondelez

Procter & Gamble

Raytheon Technologies

UnitedHealth Group

Exxon Mobil

31 Of 50 Stocks Billionaires Best Love Pay Dividends As Of February

Acceleron Pharma

Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to treat anemia in myelodysplastic syndromes (MDS) patients with ring sideroblasts. It is a low-risk subtype of blood cancer in which red blood cells contain a ring of excess iron.

Bristol-Myers, Acceleron's Reblozyl Ok'd In Canada For MDS-Associated Anemia

A judge in Hawaii on Monday ordered Bristol-Myers Squibb Co and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from its blood thinner Plavix.

Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label

Comcast

Altria

AT&T

Valero Energy

Market veterans have seen this movie before: unfounded market optimism that lacks a real foundation of fundamental valuation but instead rests on psychological factors.

BofA Securities Warns of 5% to 10% Sell-Off: 5 Safe Dividend Stocks to Buy Now

Molecular Templates Inc (NASDAQ: MTEM) has entered into a worldwide strategic research collaboration with Bristol-Myers Squibb Co (NYSE: BMY) to discover new molecules utilizing MTEM's engineered toxin body (ETB) platform for specific oncology targets. Under the terms of the agreement, MTEM will conduct research activities to discover ETBs for multiple targets, of which Bristol Myers Squibb has selected the first target.

Molecular Templates Shares Jump On Research Pact With Bristol-Myers In Cancer Settings

Biogen

EXTON, Pa., Feb. 11, 2021 /PRNewswire/ -- With the recent additions of Novartis' Mayzent, Bristol Myers Squibb's Zeposia, and Biogen's Vumerity to the multiple sclerosis (MS) market in the United States, neurologists increasingly choose to initiate treatment by prescribing an oral...

Biogen's Vumerity and Bristol Myers Squibb's Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding Advantages Over Established Agents

Vertex Pharmaceuticals

Roche Holding AG

The Vanguard Health Care Fund (Trades, Portfolio) has released its portfolio for the fourth quarter. Major trades include selling out of Medtronic PLC (NYSE:MDT), Merck & Co Inc. (NYSE:MRK) and Roche Holding AG (XSWX:ROG).

The Vanguard Health Care Fund's Top 5 Trades of the 4th Quarter

Alphabet

Walmart

Federal Realty Investment Trust

Picking retirement stocks isn't an easy thing to do. We need some growth, but yield is nice too.

7 Retirement Stocks to Buy to Supplement Your 401k

The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.

Bristol Myers (BMY) Gets European Commission Nod for Inrebic

Exelixis

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) have announced updated data from Phase 3 CheckMate 9ER trial, evaluating the combination of former's Opdivo (nivolumab) and latter's Cabometyx (cabozantinib) drug compared to Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in the first-line treatment of advanced renal cell carcinoma. BMY will present the data at the virtual American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.

Opdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer Study

Bristol Myers (BMY) obtains FDA approval of CAR T cell therapy, Breyanzi, for the treatment of lymphoma.

Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Adjuvant Treatment with Opdivo Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients.....

Adjuvant Treatment with Opdivo (nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial

PRINCETON, N.J., & ALAMEDA, Calif.--(BUSINESS WIRE)---- $BMY #BMS--OPDIVO in Combination with CABOMETYX Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal....

OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial

News for Bristol-Myers Stock (BMY)